Trial reportMovement disorders : official journal of the Movement Disorder Society2026
Deep Brain Stimulation of the Posterior Subthalamic Area and the Subthalamic Nucleus in Tremor-Dominant Parkinson's Disease: A Randomized, Crossover Trial.
Trial report in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05382858 (Deep Brain Stimulation of the Posterior Subthalamic Area), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Deep Brain Stimulation of the Posterior Subthalamic Area (PSA) Versus Subthalamic Nucleus (STN) for Tremor-dominant Parkinson's Disease: a Prospective, Randomized, Double-blinded, Cross-over Trial
Who cites it
1 citing paper in PubMed.
- Impact of PSA- versus STN-DBS on effective connectivity in Parkinson's disease - a 3.0T resting-state fMRI study.NPJ Parkinson's disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe posterior subthalamic area (PSA) is a familiarized target for Parkinson's disease (PD) in the lesioning era and has recently been reconsidered for deep brain stimulation (DBS).
objectiveThe aim of this study was to compare the therapeutic efficacy of PSA versus subthalamic nucleus (STN) DBS in tremor-dominant Parkinson's disease (TD-PD).
methodsThis single-center, randomized, crossover trial was conducted at Ruijin Hospital, Shanghai, China, from June 2022 to August 2025. Patients with TD-PD received bilateral DBS implants via a single trajectory targeting both PSA and STN. Participants received 2 months of PSA stimulation followed by 2 months of STN stimulation or vice versa, with blinded programming and evaluation. The primary outcome was the difference in off medication improvement from baseline to the end of each stimulation period in the tremor subscore of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale Part III (MDS UPDRS-III; ClinicalTrials.gov, NCT05382858).
resultsOf the 40 patients assessed for eligibility, 27 were randomly assigned and 19 completed the randomized crossover phase. Both PSA-DBS and STN-DBS significantly reduced the MDS UPDRS-III tremor subscore (baseline, 17.5 [3.3]; PSA, 4.5 [2.8]; STN, 8.0 [5.3]; P < 0.001 for both). PSA-DBS achieved greater tremor suppression than STN-DBS (adjusted mean difference -3.3; 95% confidence interval [CI]: -5.4 to -1.3; P = 0.004). STN-DBS led to greater balance improvement (adjusted mean difference -1.7; 95% CI: -2.6 to -0.7; P = 0.002). Three cases of abnormal impedance occurred. Other adverse effects were mostly stimulation related and could be resolved with reprogramming.
conclusionsGiven the limited sample size and study attrition, these findings should be considered hypothesis generating. Nonetheless, PSA-DBS appears to be a safe and effective alternative or complementary target to STN in treating TD-PD and warrants further investigation in larger, definitive trials. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.